Agilent Technologies (NYSE:A) Coverage Initiated by Analysts at Morgan Stanley

Stock analysts at Morgan Stanley initiated coverage on shares of Agilent Technologies (NYSE:A) in a report released on Tuesday, MarketBeat reports. The brokerage set an “overweight” rating on the medical research company’s stock.

Other research analysts have also issued research reports about the stock. JPMorgan Chase & Co. raised their price objective on shares of Agilent Technologies from $165.00 to $180.00 and gave the company an “overweight” rating in a research note on Tuesday, November 25th. Wall Street Zen upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. Barclays boosted their price target on shares of Agilent Technologies from $145.00 to $165.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 25th. Evercore ISI increased their price objective on Agilent Technologies from $128.00 to $140.00 and gave the company an “in-line” rating in a research note on Tuesday, October 7th. Finally, Wells Fargo & Company lifted their target price on Agilent Technologies from $150.00 to $175.00 and gave the company an “overweight” rating in a report on Tuesday, November 25th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $161.08.

Agilent Technologies Trading Down 1.9%

NYSE:A traded down $2.87 during trading hours on Tuesday, reaching $145.45. 2,142,061 shares of the stock were exchanged, compared to its average volume of 1,920,651. Agilent Technologies has a twelve month low of $96.43 and a twelve month high of $160.27. The business has a 50-day moving average of $144.40 and a two-hundred day moving average of $127.69. The company has a market capitalization of $41.24 billion, a price-to-earnings ratio of 31.83, a PEG ratio of 4.33 and a beta of 1.27. The company has a quick ratio of 1.52, a current ratio of 1.96 and a debt-to-equity ratio of 0.45.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Monday, November 24th. The medical research company reported $1.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.01. Agilent Technologies had a return on equity of 25.20% and a net margin of 18.75%.The firm had revenue of $1.86 billion for the quarter, compared to the consensus estimate of $1.83 billion. During the same quarter in the previous year, the business earned $1.46 EPS. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. Agilent Technologies has set its Q1 2026 guidance at 1.350-1.380 EPS and its FY 2026 guidance at 5.860-6.000 EPS. On average, equities analysts predict that Agilent Technologies will post 5.58 EPS for the current year.

Insider Activity at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 911 shares of the business’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $143.24, for a total value of $130,491.64. Following the completion of the transaction, the chief executive officer directly owned 32,058 shares of the company’s stock, valued at $4,591,987.92. The trade was a 2.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Rodney Gonsalves sold 3,000 shares of the company’s stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $154.99, for a total value of $464,970.00. Following the completion of the sale, the vice president owned 31,846 shares in the company, valued at $4,935,811.54. This represents a 8.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 16,401 shares of company stock worth $2,468,962 over the last quarter.

Institutional Investors Weigh In On Agilent Technologies

Several hedge funds have recently modified their holdings of the company. Saranac Partners Ltd acquired a new position in shares of Agilent Technologies in the third quarter valued at approximately $110,000. Allworth Financial LP raised its holdings in Agilent Technologies by 55.5% in the 3rd quarter. Allworth Financial LP now owns 11,389 shares of the medical research company’s stock valued at $1,462,000 after acquiring an additional 4,064 shares during the last quarter. Swiss Life Asset Management Ltd lifted its stake in shares of Agilent Technologies by 7.7% during the 3rd quarter. Swiss Life Asset Management Ltd now owns 68,703 shares of the medical research company’s stock worth $8,818,000 after purchasing an additional 4,928 shares during the period. Groupama Asset Managment boosted its holdings in shares of Agilent Technologies by 109.1% during the third quarter. Groupama Asset Managment now owns 4,756 shares of the medical research company’s stock worth $610,000 after purchasing an additional 2,482 shares during the last quarter. Finally, Investment Research Partners LLC purchased a new stake in shares of Agilent Technologies in the third quarter valued at $421,000.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.